Personalized Medicine for Liver Disease

Guest Editor:

Dr. Giuseppe Marrone
Internal Medicine and Gastroenterology Area, Fondazione Policlinico Universitario A. Gemelli, Catholic University of Rome, 00168 Rome, Italy

Deadline for manuscript submissions:
closed (15 May 2022)

Message from the Guest Editor

Dear Colleagues,

Hepatology has been facing revolutionary changes in recent years. Starting from the end of 2013, the advent of IFN-free antiviral treatments has dramatically changed the management and prognosis of HCV infection, at all stages of liver disease. The easier eradication of HCV infections on one hand and the epidemic of metabolic syndrome and non-alcoholic fatty liver disease (NAFLD) on the other are drastically modifying the epidemiology of liver disease worldwide.

In this scenario, the need for personalized diagnostic and therapeutic approaches is dramatically growing. Considering the increasing complexity of the management of chronic liver disease and the potential use of new and expensive treatments, genetics and biomarkers will allow to offer the right treatment to the right patient, thus reducing the risk of adverse events.

In this Special Issue, the advances in personalized medicine in liver diseases will be presented. Papers focusing on the individualization of diagnosis and treatment of chronic liver disease, cirrhosis, and its complications will be evaluated for publication.

Dr. Giuseppe Marrone
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us